TY - JOUR T1 - Point-of-care therapeutic drug monitoring of adalimumab by integrating a FO-SPR biosensor in a self-powered microfluidic cartridge. AU - Qu,Jia-Huan, AU - Ordutowski,Henry, AU - Van Tricht,Charlotte, AU - Verbruggen,Ruben, AU - Barcenas Gallardo,Alicia, AU - Bulcaen,Mattijs, AU - Ciwinska,Marta, AU - Gutierrez Cisneros,Carolina, AU - Devriese,Christophe, AU - Guluzade,Sona, AU - Janssens,Xander, AU - Kornblum,Sophie, AU - Lu,Yuansheng, AU - Marolt,Nika, AU - Nanjappan,Chezhiyan, AU - Rutten,Eline, AU - Vanhauwaert,Eline, AU - Geukens,Nick, AU - Thomas,Debby, AU - Dal Dosso,Francesco, AU - Safdar,Saba, AU - Spasic,Dragana, AU - Lammertyn,Jeroen, Y1 - 2022/03/02/ PY - 2021/08/16/received PY - 2022/01/31/revised PY - 2022/02/20/accepted PY - 2022/3/8/pubmed PY - 2022/4/15/medline PY - 2022/3/7/entrez KW - Adalimumab KW - Fiber-optic surface plasmon resonance KW - Patient blood plasma KW - Point of care KW - Self-powered microfluidics KW - Therapeutic drug monitoring SP - 114125 EP - 114125 JF - Biosensors & bioelectronics JO - Biosens Bioelectron VL - 206 N2 - Disease treatment with advanced biological therapies such as adalimumab (ADM), although largely beneficial, is still costly and suffers from loss of response. To tackle these aspects, therapeutic drug monitoring (TDM) is proposed to improve treatment dosing and efficacy, but is often associated with long sampling-to-result workflows. Here, we present an in-house constructed ADM-sensor, allowing TDM of ADM at the doctor's office. This biosensor brings fiber optic surface plasmon resonance (FO-SPR), combined with self-powered microfluidics, to a point of care (POC) setting for the first time. After developing a rapid FO-SPR sandwich bioassay for ADM detection on a commercial FO-SPR device, this bioassay was implemented on the fully-integrated ADM-sensor. For the latter, we combined (I) a gold coated fiber optic (FO) probe for bioassay implementation and (II) an FO-SPR readout system with (III) the self-powered iSIMPLE microfluidic technology empowering plasma sample and reagent mixing on the-cartridge as well as connection to the FO-SPR readout system. With a calculated limit of detection (LOD) of 0.35 μg/mL in undiluted plasma, and a total time-to-result (TTR) within 12 min, this innovative biosensor demonstrated a comparable performance to existing POC biosensors for ADM quantification in patient plasma samples, while requiring only 1 μL of plasma. Whereas this study demonstrates great potential for FO-SPR biosensing at the POC using ADM as a model case, it also shows huge potential for bedside TDM of other drugs (e.g. other immunosuppressants, anti-epileptics and antibiotics), as the bioassay is highly amenable to adaptation. SN - 1873-4235 UR - https://www.unboundmedicine.com/medline/citation/35255315/Point_of_care_therapeutic_drug_monitoring_of_adalimumab_by_integrating_a_FO_SPR_biosensor_in_a_self_powered_microfluidic_cartridge_ DB - PRIME DP - Unbound Medicine ER -